Trial reports describe a profile broadly consistent with incretin-based therapies, with gastrointestinal effects commonly noted, often during dose escalation
Through regular follow-ups and ongoing support, we monitor progress, adjust treatments as needed, and ensure patients receive the highest standard of care
22% of American adults said they found the cost very difficult to manage, with a similar share among insured users (23%)
Similarly, individuals who have a history of gastrointestinal issues may want to avoid Mounjaro. Smith added that you should talk with your doctor about your medical history to determine which drug may be better for you
How soon will I see results from peptide therapy
That tracks with what many of us see in practice, that these drugs work, but access is inconsistent and often depends on coverage luck